Diabetic Foot UlcersPhase 3NCT00859599
Monochromatic Phototherapy on Diabetic Foot Ulcers
A Phase 3 study testing Monochromatic phototherapy, Biolight® and Monochromatic phototherapy in people with Diabetic Foot Ulcers, run by Biolight AB at 7 sites in Sweden.
Trial summary
The purpose of this study is to evaluate the efficacy and safety of monochromatic phototherapy (Biolight®) on foot ulcers in diabetic patients, in comparison of placebo phototherapy as a complementary to standard diabetic foot ulcer therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetic Foot Ulcers
- What is being tested?
- Monochromatic phototherapy, Biolight® and Monochromatic phototherapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 107 participants
- Where
- 7 sitesSweden
- Study dates
- Aug 2008to Apr 2012
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Wagner grade 1-2 (superficial or deep ulcer)
- Size of ulcer 1 -25 cm2
- Localisation of the ulcer below the ankle
- Systolic ankle blood pressure >80 mmHg or
- Systolic toe blood pressure >45 mmHg equal to and higher than or only
- Type 1 or II diabetes - Previously known diabetes according to WHO criteria
Show all 10Show fewer
- HbA1c <12
- > 18 year
- Willing and able to fulfil the study requirements
- Written informed consent
Who cannot join
- Earlier participation in this study
- Life-threatening malignancy
- Systemic, oral use of corticosteroid preparations (> 7.5 mg Prednisolon)
- Immunosuppressive treatment such as cytostatic drugs and TNF-antagonists
- Kidney insufficiency (Creatinine >250 micromol/l)
- Clinical signs of infections
Show all 14Show fewer
- Antibiotic treatment the last two weeks
- Suspected venous genesis
- More than two ulcers per foot
- Wagner grade 3-5
- Location of ulcers making treatment or evaluation not feasible
- Photosensitivity or other sensitivity to electromagnetic radiation
- Pregnancy or breastfeeding
- Participation in any clinical study the last three month
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
Sweden7 sites, 4 recruiting
- Recruiting
Department of Medicine
Ängelholm, Skåne County, SE-452 80
Anders Nilsson, Dr, +46 431 817 85, anders.l.nilsson@skane.se
Anders Nilsson, Dr
- Terminated
Frölunda Specialistsjukhus
Gothenburg, SE-421 22
- Recruiting
Regional Hospital, Halmstad
Halmstad, SE-301 85
Stefan Sjöberg, Ass prof, +46 35 17 43 96, Stefan.sjoberg@lthalland.se
Stefan Sjöberg, Ass prof
- Terminated
Karolinska University Hospital
Huddinge, SE-141 86
- Recruiting
Lund University Hospital
Lund, SE-221 85
Magnus Löndahl, Dr, +46 46 17 22 35, Magnus.Londahl@skane.se
Per Katzman, Ass prof, +46 46 17 22 35, Per.Katzman@skane.se
- Recruiting
Malmö University Hospital
Malmö, SE-205 02
Jan Apelqvist, Ass prof, +46 40 33 23 84, jan.apelqvist@skane.se
Jan Apelqvist, Ass Prof
- Terminated
Uddevalla Hospital
Uddevalla, SE-451 80
About this study
Official title: Monochromatic Phototherapy on Diabetic Foot Ulcers. A Twenty Weeks Prospective, Randomised, Double Blind, Multi-centre, Placebo Controlled Study
The purpose of this study is to evaluate the efficacy and safety of monochromatic phototherapy (Biolight®) on foot ulcers in diabetic patients, in comparison of placebo phototherapy as a complementary to standard diabetic foot ulcer therapy.
The study initiated with a four week long Run In Period to eliminate spontaneous healing ulcer to be included. Treatment with monochromatic phototherapy (Biolight® or placebo) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan. The area of the ulcer will be measured once weekly for 20 weeks or until the ulcer is completely healed.
Read the detailed description
Description of Biolight® Therapy and device The therapy works by applying, for each indication, a specific combination of pulsating monochromatic light to specific areas of the body. The therapy is non-invasive, non-thermal, and based on the effects of pulsed monochromatic light in the visible or near-visible spectrum.
The Biolight® Therapy - mechanism of action Light is a pre-requisite for most living organisms, and human being have learnt to use light in many different situations, not least in health care, where light is widely used in various therapeutic contexts every day. X-ray is used as an investigational tool. In treating skin diseases, such as psoriasis, we use UV radiation. Laser has been successful, both in surgery and for pain relief, and white light treatment is recommended in seasonal depressions
Light is in fact electromagnetic radiation using various wavelengths. These wavelengths are perceived as different colours. Red and violet light consist of long and shorter wavelength respectively. Light consisting of all the wavelengths is perceived as white. There is an electromagnetic field in light containing energy, which can be used in different treatment situations.
In the healing process of wounded tissue basal components need access to energy and oxygen. If the amount of energy is insufficient, the healing process is retarded. By the use of monochromatic light, having a predetermined energy level and a specific wavelength, we can contribute to the expected amount of energy demand. Applied at a chosen pulse frequency and for a carefully calculated period of time, the wounded cells are provided with energy, increasing their activity as well as the oxygen supply in the damaged area. That may promote a faster healing.
The Biolight Therapy is suggested to shorten treatment time and reduce treatment costs and to improve quality of life. This non-invasive treatment is thought to be complementary to traditional therapies. The method is simple, painless and without known side effects.
The Biolight Care Device The Biolight® Care Device is a CE-marked medical device certified in accordance with the Medical Device Directive (MDD; 93/42/EEC), with the size of the palm of the hand.
The device contains 30 diodes emitting infrared light at 956 nm and also 80 diodes emitting red light at 637 nm. Infrared and red pulsed monochromatic light are used in a unique triple-stepped sequence. Infrared light, with an irradiance of ~55 W/m2, is combined with red light, with an irradiance of ~21 W/m2. Using a duty cycle of 80%, both infrared and red light are pulsed at the following frequencies during the first week: infrared/red 78 Hz, infrared/red 702 Hz, infrared/red 8572,2Hz and from the second week: infrared/red 15,6 Hz, infrared/red 287 Hz, infrared/red124 Hz. The choice of pulse frequencies and wavelengths are based on earlier observations in both in-vitro and in-vivo studies. The equipment for both monochromatic phototherapy and placebo (no irradiance output from the diodes) is identical in appearance.
Previous studies - light therapy Treatment with pulsed electromagnetic fields for 40 minutes improves micro vascular perfusion of the skin (1). In a literature overview from 1965 to 2003 on low-laser therapy for wound healing, focusing on both in vitro models and in vivo animal and human studies, some studies reported increased cell proliferation and collagen production; improvements in surgical wound healing were found in a rodent model; and, in humans, beneficial effects on superficial wound healing found in small case series have not been replicated in larger studies (2). In none of the reviewed studies was the exact mechanism of photo thermal, photochemical or photomechanical action, reported.
The precise mode of action of low-laser therapy on wound healing is still unknown (2). In a meta-analytic study of 34 peer-reviewed papers on the efficacy of low-power lasers in tissue repair, a positive effect was shown on collagen formation, rate of healing, tensile strength, and time needed for wound closure (3). In an experimental study on pressure ulcers in mice, a significant positive effect was shown on wound healing after treatment with low-laser therapy and this effect was independent of the temperature on the skin surface (4). In a systematic review of the effects of low-level laser therapy on wound healing in cell studies and animal model experiments by Lucas et al. (5), the 36 included studies contained 49 outcome parameters, of which 30 reported the positive effect of laser irradiation and 19 did not. The methodological quality of many studies was poor, and in-depth analysis of the studies with the highest methodological quality scores showed no significant pooled effect in favour of treatment (5).
A study of 20 spinal cord-injured patients with 22 pressure ulcers showed faster healing with a combination of ultrasound/ultraviolet-C and laser treatment, compared with nursing care alone (6). In a prospective, observer-blinded, multicenter randomized clinical study on the efficacy of low-level laser therapy in 86 patients with stage III decubitus ulcers, no evidence was found that justified the use of low-level laser therapy (7).
Previous studies - Biolight® A double-blind randomized placebo-controlled study on pressure ulcer in elderly patients showed a statistically significant difference between patients treated with monochromatic pulsating light (Biolight®) or placebo together with standard care. This study was conducted on 163 patients as a multi-centre study at 9 centres in Sweden and Denmark (8, 9). The mean normalised reduction in pressure ulcer size at week 12 was 0.79 for the phototherapy group and 0.50 for the placebo group (95 % CI 0.01-0.53; p=0.039). No serious side effects were noted. The conclusion was that monochromatic pulsating light fastened healing in grade II pressure ulcers in elderly patients.
A sub group analysis for the patient with diabetic foot ulcer in the above study showed a strong tendency to improved healing (diff 71.3%).
A controlled, randomised, open study on the effect of Biolight® phototherapy in comparison to conventional treatment in 74 patients with grade II or III chronic pressure ulcers was conducted at Huddinge hospital (10). This study showed a statistically significant decreased time to healing, in the phototherapy treated group compared with the control group.
A clinical study of 26 elderly patients with decubitus ulcers showed that monochromatic phototherapy, Biolight®, had an effect on the microcirculation in the edge of the decubitus ulcer with an increase of the oxygen supply to the tissue. (12).
Two in-vitro studies on the growth of skin fibroblast cells, using monochromatic phototherapy showed that the two wavelengths and the low and high pulse frequencies used in the Biolight® Wound Care program significantly influenced skin fibroblast cell growth (personal communication Kratz \& Huss Karolinska Institute, Stockholm, Sweden).
In an animal study (exposure 5 times a week during a 2-week period), with similar equipment and similar infrared and red light exposure as in the present study, no adverse effect was found (11).
Study population Diabetic patients with foot ulcers will be randomised to active phototherapeutic treatment plus standard care treatment or placebo phototherapeutic treatment plus standard care for diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcers
- Being tested
- Monochromatic phototherapy, Biolight®, Monochromatic phototherapy
- Keywords
- Monochromatic Phototherapy, Diabetic Foot Ulcers, Wound healing, Bacterial colonisation
- Medical subject headings
- Diabetic Foot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Monochromatic phototherapy, Biolight®Device
Also called Biolight® Care Device (BCD), Biolight® Wound Care Device (WCD), Monochromatic Light Therapy, Monochromatic phototherapy
Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
Monochromatic phototherapyDevice
Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A \& B, E \& F, X \& Y) the randomised patient shall receive.
Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed. Receives: Device: Monochromatic phototherapy, Biolight®; Device: Monochromatic phototherapy |
| 2 | Placebo comparator | At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A \& B, E \& F, X \& Y) the randomised patient shall receive.
Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed. Receives: Device: Monochromatic phototherapy, Biolight®; Device: Monochromatic phototherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of subjects who completely healed and time to 100% wound reduction.
Measured: 24 weeks
Secondary outcomes (1)
Time to 50% wound reduction, Subjects with increased ulcer and/or wound reduction less than 20%, Wound status, Elimination of gram-positive and anaerobic bacteria from the wound, Hospitalization caused of foot ulcer, Presence and level of amputation
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2009 (estimated)
- Study startAug 2008
- Primary completionDec 2011 (estimated)
- Study completionApr 2012 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetic Foot UlcersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 107 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Biolight AB
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Jan Apelqvist, M.D., Ph.D., Principal investigator, Malmö University Hospital, Department of Endocrinology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00859599
- Sponsor's protocol ID
- BL-039
- Other IDs
- H15:321/2008
- Status last verified
- Jun 2011
- First submitted
- 27 Feb 2009
- Last updated
- 8 Jun 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Monochromatic Phototherapy on Diabetic Foot Ulcers. A Twenty Weeks Prospective, Randomised, Double Blind, Multi-centre, Placebo Controlled Study
- ClinicalTrials.gov ID
- NCT00859599
- Acronym / sponsor ID
- BL-039
- Conditions
- Diabetic Foot Ulcers
- Keywords
- Monochromatic Phototherapy, Diabetic Foot Ulcers, Wound healing, Bacterial colonisation
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 107 participants (estimated)
- Lead sponsor
- Biolight ABIndustry (pharma, biotech, devices)
- Study start
- Aug 2008
- Primary completion
- Dec 2011 (estimated)
- Study completion
- Apr 2012 (estimated)
- First posted
- 11 Mar 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the efficacy and safety of monochromatic phototherapy (Biolight®) on foot ulcers in diabetic patients, in comparison of placebo phototherapy as a complementary to standard diabetic foot ulcer therapy.
The study initiated with a four week long Run In Period to eliminate spontaneous healing ulcer to be included. Treatment with monochromatic phototherapy (Biolight® or placebo) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan. The area of the ulcer will be measured once weekly for 20 weeks or until the ulcer is completely healed.
Detailed description
Description of Biolight® Therapy and device The therapy works by applying, for each indication, a specific combination of pulsating monochromatic light to specific areas of the body. The therapy is non-invasive, non-thermal, and based on the effects of pulsed monochromatic light in the visible or near-visible spectrum.
The Biolight® Therapy - mechanism of action Light is a pre-requisite for most living organisms, and human being have learnt to use light in many different situations, not least in health care, where light is widely used in various therapeutic contexts every day. X-ray is used as an investigational tool. In treating skin diseases, such as psoriasis, we use UV radiation. Laser has been successful, both in surgery and for pain relief, and white light treatment is recommended in seasonal depressions
Light is in fact electromagnetic radiation using various wavelengths. These wavelengths are perceived as different colours. Red and violet light consist of long and shorter wavelength respectively. Light consisting of all the wavelengths is perceived as white. There is an electromagnetic field in light containing energy, which can be used in different treatment situations.
In the healing process of wounded tissue basal components need access to energy and oxygen. If the amount of energy is insufficient, the healing process is retarded. By the use of monochromatic light, having a predetermined energy level and a specific wavelength, we can contribute to the expected amount of energy demand. Applied at a chosen pulse frequency and for a carefully calculated period of time, the wounded cells are provided with energy, increasing their activity as well as the oxygen supply in the damaged area. That may promote a faster healing.
The Biolight Therapy is suggested to shorten treatment time and reduce treatment costs and to improve quality of life. This non-invasive treatment is thought to be complementary to traditional therapies. The method is simple, painless and without known side effects.
The Biolight Care Device The Biolight® Care Device is a CE-marked medical device certified in accordance with the Medical Device Directive (MDD; 93/42/EEC), with the size of the palm of the hand.
The device contains 30 diodes emitting infrared light at 956 nm and also 80 diodes emitting red light at 637 nm. Infrared and red pulsed monochromatic light are used in a unique triple-stepped sequence. Infrared light, with an irradiance of ~55 W/m2, is combined with red light, with an irradiance of ~21 W/m2. Using a duty cycle of 80%, both infrared and red light are pulsed at the following frequencies during the first week: infrared/red 78 Hz, infrared/red 702 Hz, infrared/red 8572,2Hz and from the second week: infrared/red 15,6 Hz, infrared/red 287 Hz, infrared/red124 Hz. The choice of pulse frequencies and wavelengths are based on earlier observations in both in-vitro and in-vivo studies. The equipment for both monochromatic phototherapy and placebo (no irradiance output from the diodes) is identical in appearance.
Previous studies - light therapy Treatment with pulsed electromagnetic fields for 40 minutes improves micro vascular perfusion of the skin (1). In a literature overview from 1965 to 2003 on low-laser therapy for wound healing, focusing on both in vitro models and in vivo animal and human studies, some studies reported increased cell proliferation and collagen production; improvements in surgical wound healing were found in a rodent model; and, in humans, beneficial effects on superficial wound healing found in small case series have not been replicated in larger studies (2). In none of the reviewed studies was the exact mechanism of photo thermal, photochemical or photomechanical action, reported.
The precise mode of action of low-laser therapy on wound healing is still unknown (2). In a meta-analytic study of 34 peer-reviewed papers on the efficacy of low-power lasers in tissue repair, a positive effect was shown on collagen formation, rate of healing, tensile strength, and time needed for wound closure (3). In an experimental study on pressure ulcers in mice, a significant positive effect was shown on wound healing after treatment with low-laser therapy and this effect was independent of the temperature on the skin surface (4). In a systematic review of the effects of low-level laser therapy on wound healing in cell studies and animal model experiments by Lucas et al. (5), the 36 included studies contained 49 outcome parameters, of which 30 reported the positive effect of laser irradiation and 19 did not. The methodological quality of many studies was poor, and in-depth analysis of the studies with the highest methodological quality scores showed no significant pooled effect in favour of treatment (5).
A study of 20 spinal cord-injured patients with 22 pressure ulcers showed faster healing with a combination of ultrasound/ultraviolet-C and laser treatment, compared with nursing care alone (6). In a prospective, observer-blinded, multicenter randomized clinical study on the efficacy of low-level laser therapy in 86 patients with stage III decubitus ulcers, no evidence was found that justified the use of low-level laser therapy (7).
Previous studies - Biolight® A double-blind randomized placebo-controlled study on pressure ulcer in elderly patients showed a statistically significant difference between patients treated with monochromatic pulsating light (Biolight®) or placebo together with standard care. This study was conducted on 163 patients as a multi-centre study at 9 centres in Sweden and Denmark (8, 9). The mean normalised reduction in pressure ulcer size at week 12 was 0.79 for the phototherapy group and 0.50 for the placebo group (95 % CI 0.01-0.53; p=0.039). No serious side effects were noted. The conclusion was that monochromatic pulsating light fastened healing in grade II pressure ulcers in elderly patients.
A sub group analysis for the patient with diabetic foot ulcer in the above study showed a strong tendency to improved healing (diff 71.3%).
A controlled, randomised, open study on the effect of Biolight® phototherapy in comparison to conventional treatment in 74 patients with grade II or III chronic pressure ulcers was conducted at Huddinge hospital (10). This study showed a statistically significant decreased time to healing, in the phototherapy treated group compared with the control group.
A clinical study of 26 elderly patients with decubitus ulcers showed that monochromatic phototherapy, Biolight®, had an effect on the microcirculation in the edge of the decubitus ulcer with an increase of the oxygen supply to the tissue. (12).
Two in-vitro studies on the growth of skin fibroblast cells, using monochromatic phototherapy showed that the two wavelengths and the low and high pulse frequencies used in the Biolight® Wound Care program significantly influenced skin fibroblast cell growth (personal communication Kratz \& Huss Karolinska Institute, Stockholm, Sweden).
In an animal study (exposure 5 times a week during a 2-week period), with similar equipment and similar infrared and red light exposure as in the present study, no adverse effect was found (11).
Study population Diabetic patients with foot ulcers will be randomised to active phototherapeutic treatment plus standard care treatment or placebo phototherapeutic treatment plus standard care for diabetic foot ulcers.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Device: Monochromatic phototherapy, Biolight®, Device: Monochromatic phototherapyAt the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A \& B, E \& F, X \& Y) the randomised patient shall receive. Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed. |
| 2 | Placebo comparator | Device: Monochromatic phototherapy, Biolight®, Device: Monochromatic phototherapyAt the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A \& B, E \& F, X \& Y) the randomised patient shall receive. Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Wagner grade 1-2 (superficial or deep ulcer)
- Size of ulcer 1 -25 cm2
- Localisation of the ulcer below the ankle
- Systolic ankle blood pressure >80 mmHg or
- Systolic toe blood pressure >45 mmHg equal to and higher than or only
Key exclusion criteria (14 listed)
- Earlier participation in this study
- Life-threatening malignancy
- Systemic, oral use of corticosteroid preparations (> 7.5 mg Prednisolon)
- Immunosuppressive treatment such as cytostatic drugs and TNF-antagonists
- Kidney insufficiency (Creatinine >250 micromol/l)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Monochromatic phototherapy, Biolight®Also: Biolight® Care Device (BCD), Biolight® Wound Care Device (WCD), Monochromatic Light Therapy, Monochromatic phototherapyMonochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan. | Device | 1, 2 |
| Monochromatic phototherapyMonochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan. | Device | 1, 2 |
Primary outcome
Number of subjects who completely healed and time to 100% wound reduction.
Time frame: 24 weeks
1 secondary outcome
Time to 50% wound reduction, Subjects with increased ulcer and/or wound reduction less than 20%, Wound status, Elimination of gram-positive and anaerobic bacteria from the wound, Hospitalization caused of foot ulcer, Presence and level of amputation
Time frame: 24 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2011.
Related trials for Diabetic Foot Ulcers
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruiting
Wearable Insoles for Recurrent Diabetic Ulcer Prevention
Diabetes, Peripheral Neuropathy
Active, not recruiting
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Foot, Diabetic
Not yet recruiting
Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabetic Foot Ulcer Wounds
Diabete Mellitus
Not yet recruiting
Better Care Closer to Home: Enhancing Primary and Community Care
Diabetic Foot Disease, Recurrence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jan Apelqvist, M.D., Ph.D. principal investigator
Malmö University Hospital, Department of Endocrinology
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Monochromatic phototherapy, Biolight® and Monochromatic phototherapy in people with Diabetic Foot Ulcers, run by Biolight AB at 7 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Jun 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Hans Johansson (+46 31 336 91 02, hans.johansson@biolight.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of subjects who completely healed and time to 100% wound reduction. (time frame: 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2011.